IL134246A - -2 {-3 [-4 {-2 tert-butyl - 6 trifloromethylpyridine - 4-il) piperazine-1-il] propylmarko} pyrimidine - 4 - all-pomarate and medicinal preparations containing it - Google Patents

-2 {-3 [-4 {-2 tert-butyl - 6 trifloromethylpyridine - 4-il) piperazine-1-il] propylmarko} pyrimidine - 4 - all-pomarate and medicinal preparations containing it

Info

Publication number
IL134246A
IL134246A IL13424698A IL13424698A IL134246A IL 134246 A IL134246 A IL 134246A IL 13424698 A IL13424698 A IL 13424698A IL 13424698 A IL13424698 A IL 13424698A IL 134246 A IL134246 A IL 134246A
Authority
IL
Israel
Prior art keywords
butyl
fumaric acid
fumarate
mol
acid salt
Prior art date
Application number
IL13424698A
Other languages
English (en)
Hebrew (he)
Other versions
IL134246A0 (en
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL134246A0 publication Critical patent/IL134246A0/xx
Publication of IL134246A publication Critical patent/IL134246A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13424698A 1997-08-14 1998-08-14 -2 {-3 [-4 {-2 tert-butyl - 6 trifloromethylpyridine - 4-il) piperazine-1-il] propylmarko} pyrimidine - 4 - all-pomarate and medicinal preparations containing it IL134246A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19735410A DE19735410A1 (de) 1997-08-14 1997-08-14 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
PCT/EP1998/005178 WO1999009015A1 (de) 1997-08-14 1998-08-14 2-{3-[4-(2-t-butyl-6- trifluormethylpyrimidin-4-yl) piperrazin-1-yl] propylmercapto} pyrimidin-4-ol-fumarat

Publications (2)

Publication Number Publication Date
IL134246A0 IL134246A0 (en) 2001-04-30
IL134246A true IL134246A (en) 2002-11-10

Family

ID=7839072

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13424698A IL134246A (en) 1997-08-14 1998-08-14 -2 {-3 [-4 {-2 tert-butyl - 6 trifloromethylpyridine - 4-il) piperazine-1-il] propylmarko} pyrimidine - 4 - all-pomarate and medicinal preparations containing it

Country Status (25)

Country Link
US (1) US20010020022A1 (zh)
EP (2) EP1003728B1 (zh)
JP (1) JP4444492B2 (zh)
KR (1) KR100571945B1 (zh)
CN (1) CN1267286A (zh)
AR (1) AR016605A1 (zh)
AT (1) ATE525362T1 (zh)
AU (1) AU749575B2 (zh)
BG (1) BG104122A (zh)
BR (1) BR9811177A (zh)
CA (1) CA2301297A1 (zh)
CO (1) CO4960663A1 (zh)
DE (1) DE19735410A1 (zh)
ES (1) ES2374156T3 (zh)
HU (1) HUP0003710A3 (zh)
ID (1) ID24639A (zh)
IL (1) IL134246A (zh)
NO (1) NO314935B1 (zh)
NZ (1) NZ502675A (zh)
PL (1) PL201927B1 (zh)
SK (1) SK1182000A3 (zh)
TR (1) TR200000406T2 (zh)
TW (1) TW467912B (zh)
WO (1) WO1999009015A1 (zh)
ZA (1) ZA987239B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087917A1 (en) * 2000-03-27 2003-05-08 Dorothea Strack Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
WO2006015842A1 (en) * 2004-08-09 2006-02-16 Abbott Gmbh & Co. Kg 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
EP2906221B1 (en) 2012-10-11 2019-05-15 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung

Also Published As

Publication number Publication date
WO1999009015A1 (de) 1999-02-25
EP1003728A1 (de) 2000-05-31
KR20010022833A (ko) 2001-03-26
NZ502675A (en) 2001-06-29
HUP0003710A3 (en) 2002-01-28
BG104122A (en) 2000-11-30
DE19735410A1 (de) 1999-02-18
AU9342698A (en) 1999-03-08
EP1003728B1 (de) 2011-09-21
ID24639A (id) 2000-07-27
IL134246A0 (en) 2001-04-30
EP2272833A1 (de) 2011-01-12
NO20000665D0 (no) 2000-02-10
ES2374156T3 (es) 2012-02-14
KR100571945B1 (ko) 2006-04-18
AU749575B2 (en) 2002-06-27
NO314935B1 (no) 2003-06-16
CA2301297A1 (en) 1999-02-25
ZA987239B (en) 2000-02-14
JP4444492B2 (ja) 2010-03-31
CO4960663A1 (es) 2000-09-25
PL338603A1 (en) 2000-11-06
CN1267286A (zh) 2000-09-20
TW467912B (en) 2001-12-11
US20010020022A1 (en) 2001-09-06
NO20000665L (no) 2000-02-10
AR016605A1 (es) 2001-07-25
BR9811177A (pt) 2000-07-25
JP2001515070A (ja) 2001-09-18
ATE525362T1 (de) 2011-10-15
SK1182000A3 (en) 2000-09-12
PL201927B1 (pl) 2009-05-29
TR200000406T2 (tr) 2000-05-22
HUP0003710A2 (hu) 2001-10-28

Similar Documents

Publication Publication Date Title
SI9520080A (sl) Substituirane pirimidinske spojine in njihova uporaba
JP2010527348A (ja) Ｈｓｐ９０阻害剤としてのキナゾリン−オキシム誘導体
HUE024898T2 (en) New pyrimidine compound with dibenzylamine structure and drug containing compound
US3944551A (en) N-Coumaranyl and chromanyl -methyl-or sulfur analogs thereof-N'- thiazolyl piperazines
CA2527037A1 (en) 2,3-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators
US4575508A (en) 2-Substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines, and their use as antiarrhythmic agents
US6503909B1 (en) Pyrazine compounds
IE901665L (en) Arylthiazolylmethylimidazoles
JP3159526B2 (ja) ２−アミノピリミジン−４−カルボキサミド誘導体、その製法及びその用途
KR20020016872A (ko) 신규한 피페라지닐알킬티오피리미딘 유도체, 그것을함유하는 약제 조성물, 및 활성성분의 제조방법
KR20010015787A (ko) 테트라히드로피리도피리미디논의 제3 위치 치환 유도체,그의 제조 방법 및 용도
IL134246A (en) -2 {-3 [-4 {-2 tert-butyl - 6 trifloromethylpyridine - 4-il) piperazine-1-il] propylmarko} pyrimidine - 4 - all-pomarate and medicinal preparations containing it
JPH07138238A (ja) 新規キナゾリン誘導体およびそれを有効成分とする抗腫瘍剤
US6486162B2 (en) 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate
GB2171997A (en) 4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives
JP2856912B2 (ja) Ｃｎｓ活性を示すトラゾドンのアルキル誘導体
WO1995019345A1 (fr) Derive du diazacycloalcanealkylsufonamide
JPH05202054A (ja) アミノメチル置換２，３−ジヒドロピラノ〔２，３−ｂ〕ピリジン類
MXPA00001161A (en) 2-{3-[4-(2-T-BUTYL-6- TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL]PROPYLMERCAPTO}PYRIMIDIN-4-OL-FUMARATE
CZ2000450A3 (cs) Sůl 2-[3-/4-(2-terc.-butyl-6-trifluormethyl-4- pyrimidinyl)-1-piperazinyl/propylthio]-4- pyrimidínolu s kyselinou fumarovou
JPS61148144A (ja) フエニル酪酸誘導体
EP0707587A1 (en) PHARMACEUTICAL EFFECTIVE ENANTIOMERS
JPH051065A (ja) キサンチン誘導体
CN100354282C (zh) 噻吩并哒嗪酮及其在调节自身免疫疾病中的用途
KR820001338B1 (ko) 벤질 피리미딘의 제조방법

Legal Events

Date Code Title Description
FF Patent granted
HP Change in proprietorship
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees